Source: International Congress 2018 – Experimental research in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Ma (Beijing, China), L. Qi (Beijing, China), H. Zhang (Beijing, China), S. Zhang (Beijing, China), F. He (Beijing, China), G. Wang (Beijing, China), Z. Feng (Beijing, China), S. Li (Beijing, China). BMPR2 mRNA functioning as competing endogenous RNA in pulmonary arterial hypertension associated with systemic-to-pulmonary shunts. 3058

Member's Comments

No comment yet.

Related content which might interest you: Towards an understanding of pulmonary arterial hypertension (PAH): gene regulation patterns in pulmonary arterial resistance vessels of patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 Endothelial control of BMPR2 signalling in experimental shunt-induced pulmonary arterial hypertension Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling Year: 2005 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Relationship of BMPR2 mutations and vasoreactivity in pulmonary arterial hypertension Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling Year: 2005 BMPR2 mutations and iron metabolism in pulmonary arterial hypertension patients Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Right ventricular and pulmonary vascular interaction in pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases Year: 2008 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 1195-1198 Year: 2014 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005